Abstract:Various human malignancies are characterized by excessive activation of the Janus family of cytoplasmic tyrosine kinases (JAK) and their associated transcription factors STAT3 and STAT5. In the majority of solid tumors, this occurs in response to increased abundance of inflammatory cytokines in the tumor microenvironment prominently produced by infiltrating innate immune cells. Many of these cytokines share common receptor subunits and belong to the interleukin (IL)-6/IL-11, IL-10/IL-22 and IL-12/IL-23 families. Therapeutic inhibition of the JAK/STAT3 pathway potentially offers considerable benefit owing to the capacity of JAK/STAT3 signaling to promote cancer hallmarks in the tumor and its environment, including proliferation, survival, angiogenesis, tumor metabolism while suppressing antitumor immunity. This is further emphasized by the current successful clinical applications of JAK-specific small molecule inhibitors for the treatment of inflammatory disorders and hematopoietic malignancies. Here we review current preclinical applications for JAK inhibitors for the treatment of solid cancers in mice, with a focus on the most common malignancies emanating from oncogenic transformation of the epithelial mucosa in the stomach and colon. Emerging data with small molecule JAK-specific adenosine triphosphate-binding analogs corroborate genetic findings and suggest that interference with the JAK/STAT3 pathway may suppress the growth of the most common forms of sporadic colon cancers that arise from mutations of the APC tumor suppressor gene. Likewise inhibition of cytokine-dependent activation of the JAK/STAT3 pathway may also afford orthogonal treatment opportunities for other oncogene-addicted cancer cells that have gained drug resistance.

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers

Advances in the Research of JAK2 Abnormalities in Heamatological Disorders

Nuclear JAK2: Form and Function in Cancer

Janus kinases (JAKs): The efficient therapeutic targets for autoimmune diseases and myeloproliferative disorders

Janus Kinases (jaks): the Efficient Therapeutic Targets for Autoimmune Diseases and Myeloproliferative Disorders.

Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

The JAK/STAT signaling pathway: from bench to clinic

[Inhibitors of JAK2/STAT Signaling Pathway and Hematologic Malignancies-Review].

Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions

Dual-target Janus Kinase (JAK) Inhibitors: Comprehensive Review on the JAK-based Strategies for Treating Solid or Hematological Malignancies and Immune-Related Diseases.

Constitutive Activation of JAK/STAT Signaling Pathway in Leukemogenesis

CBL Family E3 Ubiquitin Ligases Control JAK2 Ubiquitination and Stability in Hematopoietic Stem Cells and Myeloid Malignancies

Targeting the JAK/STAT pathway in solid tumors

Roles of Germline JAK2 Activation Mutation JAK2 V625F in the Pathology of Myeloproliferative Neoplasms

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

Potential applications of JAK inhibitors, clinically approved drugs against autoimmune diseases, in cancer therapy

Molecular basis of JAK2 H608Y and H608N mutations in the pathology of acute myeloid leukemia

JAK/STAT in leukemia: a clinical update

The Effects of R683S (G) Genetic Mutations on the JAK2 Activity, Structure and Stability.